Recent research introduces innovative compounds aimed at modulating Bruton’s tyrosine kinase (BTK) and WEE1 kinase, key regulators in cancer cell survival and proliferation. Shanghai Helioson Pharmaceutical presented PROTAC degraders inducing BTK degradation, while Bristol-Myers Squibb spotlighted WEE1 degrader BMS-986463 as a pan-cancer strategy attacking tumor cells reliant on DNA damage checkpoints. These novel modalities signal progress in targeted oncology therapeutics.